Publication | Open Access

An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck

Il-15-based Superagonist Alt-803ImmunologyImmunologic MechanismNk Cell ResponseAutoimmunityImmune Checkpoint InhibitorHead And Neck CancerImmunotherapyMedicineCell BiologyTumor MicroenvironmentCancer Research